Singapore markets closed
Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,102.48 -1,241.54 (-1.93%) CMC Crypto 200
1,304.48 -92.06 (-6.59%)
Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 44.70 |
| Open | 44.68 |
| Bid | 44.91 x 800 |
| Ask | 44.90 x 1000 |
| Day's range | 44.34 - 45.37 |
| 52-week range | 44.34 - 69.10 |
| Volume | |
| Avg. volume | 16,092,461 |
| Market cap | 90.9B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.10 |
| Earnings date | 26 Jul 2024 |
| Forward dividend & yield | 2.40 (5.35%) |
| Ex-dividend date | 04 Apr 2024 |
| 1y target est | 54.24 |
ZacksThe Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Business WireCHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
PRINCETON, N.J., April 26, 2024--CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine....
GuruFocus.comBeyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)
A Strategic SWOT Insight into Bristol-Myers Squibb's Financials and Future
© 2024 Yahoo. All rights reserved.